Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited)

v3.21.1
Condensed Consolidated Statements of Changes in Stockholder's Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock
Preferred Stock
Additional paid in capital
Accumulated deficit
Balance at the beginning (in shares) at Dec. 31, 2019   44,384,222 2,857,143    
Balance at the beginning at Dec. 31, 2019 $ 20,995 $ 44 $ 3 $ 135,239 $ (114,291)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Conversion to common stock (in shares)   8,000,000 (1,600,000)    
Conversion of preferred stock to common stock 0 $ 8 $ (2) (6)  
Issuance of shares related to Aevi Merger (in shares)   3,893,361      
Issuance of shares related to Aevi Merger 15,496 $ 4   15,492  
Issuance of shares pursuant to registered direct offering, net of offering costs (in shares)   1,306,282      
Issuance of shares pursuant to registered direct offering, net of offering costs 5,136 $ 1   5,135  
Issuance of shares pursuant to common stock private placement, net of offering costs (in shares)   1,951,219      
Issuance of shares pursuant to common stock private placement, net of offering costs 3,888 $ 2   3,886  
Exercise of stock options and warrants (in shares)   25,168      
Exercise of stock options and warrants 74     74  
Stock-based compensation 1,116     1,116  
Net loss (21,117)       (21,117)
Balance at the end (in shares) at Mar. 31, 2020   59,560,252 1,257,143    
Balance at the end at Mar. 31, 2020 25,588 $ 59 $ 1 160,936 (135,408)
Balance at the beginning (in shares) at Dec. 31, 2020   75,004,127 1,257,143    
Balance at the beginning at Dec. 31, 2020 24,562 $ 75 $ 1 202,276 (177,790)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of shares of common stock in underwritten public offering, net of offering costs (in shares)   13,971,889      
Issuance of shares of common stock and pre-funded warrants in underwritten public offering, net 37,653 $ 14   37,639  
Conversion to common stock (in shares)   6,285,715      
Exercise of stock options and warrants (in shares)   128,800      
Exercise of stock options and warrants 172     172  
Stock-based compensation 1,448     1,448  
Net loss (30,680)       (30,680)
Balance at the end (in shares) at Mar. 31, 2021   89,104,816 1,257,143    
Balance at the end at Mar. 31, 2021 $ 33,155 $ 89 $ 1 $ 241,535 $ (208,470)